Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
4
Mins
5 Dec 2023
Pregnancy After Breast Cancer: Is it Safe?
AN INSIGHTFUL session featuring a debate analysed the safety and feasibility of pregnancy amongst survivors of early breast cancer (EBC) at…
10
Mins
5 Dec 2023
Current and Upcoming Treatment Strategies After CDK4/6 Inhibitors for Patients With ER+/HER2- Advanced Breast Cancer
The latest recommendations and upcoming treatment strategies for patients with oestrogen-receptor positive (ER+), human epidermal growth…
2
Mins
5 Dec 2023
Reduced Diversity of
HLA
Class I Alleles May Contribute to the Early Manifestation of Breast Cancer in Carriers of the
BRCA1
Mutation
Most female carriers of germline BRCA1 mutations develop breast and/or ovarian cancer. However, the penetrance of BRCA1 pathogenic variants…
3
Mins
5 Dec 2023
The Hallmarks of Cancer in 2023
CURRENT cancer hallmarks, their capabilities, and potential targeted therapies were the focus of the presentation given by Douglas Hanahan…
1
Mins
5 Dec 2023
Precision Medicine-Based Platform to Guide the Treatment of
EML4-ALK
Lung Cancers and Other Non-Small Cell Lung Cancers
Lung cancer (LC) remains the top cause of cancer-associated mortality worldwide, with a 10-year overall survival rate of only 5%.1…
3
Mins
5 Dec 2023
Isolated Tumour Cells in Early Endometrial Carcinomas
Endometrial cancer is the most common gynaecologic malignancy in high-income countries due to increased life expectancy. Approximately…
1
Mins
5 Dec 2023
Programmed Death-Ligand 1 Expression and its Relation to
EML4-ALK
Gene Variants in Metastatic Lung Adenocarcinoma: A Single Centre Real-World Experience
Targeted therapy and immunotherapy have revolutionised the treatment of metastatic non-small cell lung cancer, particularly adenocarcinoma…
6
Mins
5 Dec 2023
ESMO 2023 Abstract Highlights
FOR the first time, there is an alternative to chemotherapy for patients with advanced or metastatic urothelial carcinoma. The results of a…
15
Mins
5 Dec 2023
Improving Inclusivity and Diversity in Clinical Trials
Although clinical trials form the backbone of evidence-based medicine, cohorts participating in clinical trials are often poorly…
6
Mins
5 Dec 2023
Dostarlimab and Radiotherapy in A Patient with MSI-H/dMMR Endometrial Cancer
Endometrial carcinoma (EC) is the world’s most common gynaecological malignancy, with a global incidence of 382,069 new cases and 89,929…
←
1
2
3
…
388
389
390
391
392
393
394
…
1,121
1,122
1,123
→
We’ve noticed you’re accessing
from
North/South America.
View
View